Our study sought to quantify risk of HHF, AMI and ischemic stroke among CRPC patients initiating AAP relative to ENZ within a national administrative claims database. Increased risk for HHF among AAP compared to ENZ users was observed. The difference in myocardial infarction did not attain statistic …
See more from Catherine Marshall
In the real world (outside of clinical trials), cardiovascular comorbidities really matter. Interesting article on the cardiovascular outcomes of patients treated with abiraterone and enzalutamide for men with mCRPC.